Organon (OGN) Free Cash Flow Growth (1y) (2021 - 2026)
Organon (OGN) Free Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Growth (1y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
1,827.56% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
-56.64% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
154.57% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
27.51% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
149.74% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
50.71% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
46.82% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
23.04% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
36.22% |
| 10 |
Organon |
3.53 Bn |
2.41 Bn |
783.00 Mn |
337.21% |
| Date | Value |
|---|
| Mar 31, 2026 |
337.21% |
| Dec 31, 2025 |
-71.34% |
| Sep 30, 2025 |
120.20% |
| Jun 30, 2025 |
-39.67% |
| Mar 31, 2025 |
43.33% |
| Dec 31, 2024 |
5.35% |
| Sep 30, 2024 |
-51.94% |
| Jun 30, 2024 |
781.82% |
| Mar 31, 2024 |
-55.88% |
| Dec 31, 2023 |
55.88% |
| Sep 30, 2023 |
-21.37% |
| Jun 30, 2023 |
-141.51% |
| Mar 31, 2023 |
-24.44% |
| Dec 31, 2022 |
1,800.00% |
| Sep 30, 2022 |
-21.08% |
| Jun 30, 2022 |
-72.54% |
| Mar 31, 2022 |
-92.87% |
| Dec 31, 2021 |
-103.31% |
| Sep 30, 2021 |
78.49% |
| Jun 30, 2021 |
-50.06% |
